| scholarly article | Q13442814 |
| P50 | author | Zhe Li | Q57050772 |
| P2093 | author name string | Jun Wu | |
| Qin Li | |||
| Zhe Li | |||
| Junxian Yu | |||
| Manyuan Wang | |||
| P2860 | cites work | Quantitative structure-activity relationship and molecular docking of artemisinin derivatives to vascular endothelial growth factor receptor 1. | Q50933431 |
| The artemisinin derivative artesunate inhibits corneal neovascularization by inducing ROS-dependent apoptosis in vascular endothelial cells | Q51048652 | ||
| Multifunctional mesoporous nanoparticles as pH-responsive Fe(2+) reservoirs and artemisinin vehicles for synergistic inhibition of tumor growth | Q53559198 | ||
| In vivostudy of effects of artesunate nanoliposomes on human hepatocellular carcinoma xenografts in nude mice | Q86889772 | ||
| Enhanced delivery of artemisinin and its analogues to cancer cells by their adducts with human serum transferrin | Q87506064 | ||
| Enhancing the in vitro anti-cancer efficacy of artesunate by loading into poly-D,L-lactide-co-glycolide (PLGA) nanoparticles | Q88162674 | ||
| Alendronate-Loaded Modified Drug Delivery Lipid Particles Intended for Improved Oral and Topical Administration. | Q50618289 | ||
| Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. | Q50782379 | ||
| Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action | Q22061792 | ||
| A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer | Q22061945 | ||
| Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells | Q28306865 | ||
| Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1 | Q28468670 | ||
| Aspirin in gastrointestinal oncology: new data on an old friend | Q30823929 | ||
| The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells. | Q30832428 | ||
| Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis | Q33384203 | ||
| Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. | Q33551142 | ||
| Preparation, characterization and in vitro efficacy of magnetic nanoliposomes containing the artemisinin and transferrin | Q33739996 | ||
| Artesunate induces apoptosis via a Bak‐mediated caspase‐independent intrinsic pathway in human lung adenocarcinoma cells | Q34179568 | ||
| Qinghaosu (artemisinin): an antimalarial drug from China | Q34193570 | ||
| The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine | Q34223139 | ||
| Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials | Q34263014 | ||
| Dihydroartemisinin Enhances Apo2L/TRAIL-Mediated Apoptosis in Pancreatic Cancer Cells via ROS-Mediated Up-Regulation of Death Receptor 5 | Q34292461 | ||
| Development of artemisinin compounds for cancer treatment | Q34296810 | ||
| Metformin in cancer prevention and therapy | Q34357983 | ||
| Dihydroartemisinin Exerts Its Anticancer Activity through Depleting Cellular Iron via Transferrin Receptor-1 | Q34382566 | ||
| Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function | Q34449959 | ||
| Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. | Q34580333 | ||
| Safety and efficacy field study of artesunate for dogs with non-resectable tumours | Q39156030 | ||
| LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics | Q39304213 | ||
| Artesunate induces G0/G1 cell cycle arrest and iron-mediated mitochondrial apoptosis in A431 human epidermoid carcinoma cells | Q39379002 | ||
| The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model. | Q39425405 | ||
| In vitro evaluation of the cytotoxic and genotoxic effects of artemether, an antimalarial drug, in a gastric cancer cell line (PG100) | Q39467093 | ||
| Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G2/M phase | Q39476200 | ||
| Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007-2015): In vivo response and dhfr and dhps mutations | Q39497780 | ||
| Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway. | Q39561270 | ||
| Anti-tumor effects of dihydroartemisinin on human osteosarcoma | Q39607993 | ||
| Artesunate mitigates proliferation of tumor cells by alkylating heme-harboring nitric oxide synthase | Q39618459 | ||
| Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells | Q39644471 | ||
| Neurotoxic mode of action of artemisinin | Q39653002 | ||
| In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents | Q39701664 | ||
| Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. | Q39731808 | ||
| Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB. | Q39770321 | ||
| Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65. | Q39804120 | ||
| The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate's activity in cancer cells. | Q39886511 | ||
| Artesunate derived from traditional Chinese medicine induces DNA damage and repair. | Q39976238 | ||
| Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin | Q39986800 | ||
| Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species | Q39991619 | ||
| Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells | Q40161891 | ||
| Artesunate in the treatment of metastatic uveal melanoma--first experiences | Q40374633 | ||
| Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system. | Q40381469 | ||
| Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent | Q41668110 | ||
| Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis | Q41719685 | ||
| Dihydroartemisinin inhibits vascular endothelial growth factor-induced endothelial cell migration by a p38 mitogen-activated protein kinase-independent pathway | Q42074384 | ||
| The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials | Q42571291 | ||
| Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo | Q42923682 | ||
| Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. | Q43170838 | ||
| Preparation and optimization of transferrin-modified-artemether lipid nanospheres based on the orthogonal design of emulsion formulation and physically electrostatic adsorption | Q44411995 | ||
| Molecular modes of action of artesunate in tumor cell lines. | Q44517624 | ||
| Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. | Q44872854 | ||
| Research advance in antitumor activities of artemisinin and its derivatives | Q46097911 | ||
| Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial | Q46777958 | ||
| A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer | Q47581209 | ||
| Dihydroartemisinin is an inhibitor of ovarian cancer cell growth | Q47776445 | ||
| Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells | Q47992452 | ||
| Antitumour effect of cimetidine | Q48088736 | ||
| Chronic thalidomide and chemoembolization for hepatocellular carcinoma | Q34641094 | ||
| Case report of a pituitary macroadenoma treated with artemether | Q34653053 | ||
| Artemether Combined with shRNA Interference of Vascular Cell Adhesion Molecule-1 Significantly Inhibited the Malignant Biological Behavior of Human Glioma Cells | Q34674201 | ||
| Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production | Q34675798 | ||
| Creation and revelation: two different routes to advancement in the biomedical sciences | Q34698856 | ||
| Dihydroartemisinin promotes angiogenesis during the early embryonic development of zebrafish | Q34740860 | ||
| Phase 0 clinical trials in oncology new drug development | Q34941964 | ||
| Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma | Q34990174 | ||
| Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors | Q35079731 | ||
| Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy | Q35832111 | ||
| An injectable hybrid nanoparticle-in-oil-in-water submicron emulsion for improved delivery of poorly soluble drugs | Q36232548 | ||
| Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. | Q37068031 | ||
| The production and exportation of artemisinin-derived drugs in China: current status and existing challenges | Q37099773 | ||
| In vitro selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemisinin | Q37119350 | ||
| The antiviral activities of artemisinin and artesunate. | Q37242654 | ||
| Novel classes of dimer antitumour drug candidates. | Q37387578 | ||
| The activation of c-Jun NH₂-terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells | Q37514559 | ||
| Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. | Q37543714 | ||
| Severe embryotoxicity of artemisinin derivatives in experimental animals, but possibly safe in pregnant women. | Q37683339 | ||
| Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. | Q37996239 | ||
| Aspirin and NSAIDs for breast cancer chemoprevention | Q38266129 | ||
| Nanoparticles and the blood-brain barrier: advancing from in-vitro models towards therapeutic significance | Q38275050 | ||
| Effects of artesunate on cytokinesis and G₂/M cell cycle progression of tumour cells and budding yeast. | Q38338694 | ||
| Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. | Q38832397 | ||
| Clinical and non-clinical safety of artemisinin derivatives in pregnancy | Q38923227 | ||
| Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors | Q38945222 | ||
| In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. | Q38968099 | ||
| Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells | Q39024885 | ||
| Cytotoxicity of dihydroartemisinin toward Molt-4 cells attenuated by N-tert-butyl-alpha-phenylnitrone and deferoxamine | Q39079492 | ||
| Artemisinin rewires the protein interaction network in cancer cells: network analysis, pathway identification, and target prediction | Q39089032 | ||
| Arteether exerts antitumor activity and reduces CD4+CD25+FOXP3+ T-reg cells in vivo | Q39090250 | ||
| Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate | Q39123470 | ||
| Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. | Q39150213 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | organic chemistry | Q11351 |
| artemisinin | Q426921 | ||
| neoplasm | Q1216998 | ||
| antineoplastic | Q2853144 | ||
| P304 | page(s) | 1331 | |
| P577 | publication date | 2016-10-07 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Molecules | Q151332 |
| P1476 | title | Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do? | |
| P478 | volume | 21 |
| Q48179606 | Alkenyl and Aryl Peroxides |
| Q43939294 | Artemisinin Derivatives Target Topoisomerase 1 and Cause DNA Damage in Silico and in Vitro |
| Q38712611 | Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action. |
| Q91366841 | Dihydroartemisinin-Bile Acid Hybridization as an Effective Approach to Enhance Dihydroartemisinin Anticancer Activity |
| Q88249511 | FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation |
| Q46307663 | MOLECULAR CLONING AND CHARACTERIZATION OF RIBOSOMAL PROTEIN S9 IN ECHINOCOCCUS GRANULOSUS. |
| Q89989620 | New drugs are not enough‑drug repositioning in oncology: An update |
| Q88800961 | Role of dihydroartemisinin in regulating prostaglandin E2 synthesis cascade and inflammation in endothelial cells |
| Q64254243 | Simultaneous Quantification of Five Sesquiterpene Components after Ultrasound Extraction in L. by an Accurate and Rapid UPLC⁻PDA Assay |
| Q93083365 | Synthesis of Artemisinin-Estrogen Hybrids Highly Active against HCMV, P. falciparum, and Cervical and Breast Cancer |
| Q94566921 | Synthesis of Tamoxifen-Artemisinin and Estrogen-Artemisinin Hybrids Highly Potent Against Breast and Prostate Cancer |
Search more.